Lecanemab Resources
In This Section
On July 6, 2023, the FDA announced the traditional approval of lecanemab (Leqembi) for treatment of Alzheimer’s disease. The AAN is preparing resources to guide members about this drug.
Recent News
- Alzheimer's Programs Ramp Up Lecanemab Therapy: It's Been a Bumpy Road (Neurology Today®) | March 21, 2024
- Lecanemab for Alzheimer Disease Is It Worth It? (Neurology®) | April 9, 2024
- Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease (Neurology®) | April 9, 2024
- New Analysis Finds Lecanemab Is Not Cost-Effective Compared With Standard Care: Why the Cost-Benefit Ratio Is Not So Simple (Neurology Today®) | April 4, 2024
- NeuroPanels: Lecanemab for Alzheimer's Disease Case Discussion | January 16, 2024
- Lecanemab: Looking Before We Leap (Neurology®) | July 21, 2023
- FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval | July 6, 2023
- The Advisory Committee unanimously voted that the results of the CLARITY AD trial provided evidence of clinical benefit for Lecanemab for the treatment of Alzheimer’s disease | June 9, 2023
- Lecanemab Prescriptions Could Increase Medicare Annual Spending by Up to $5 Billion (Neurology Today®) | May 12, 2023
- APOE Genotyping Will Play a Major Role in Lecanemab Prescribing: The Clinical, Ethical, and Financial Ramifications (Neurology Today®) | April 20, 2023
- Considering Lecanemab for Alzheimer's Disease? Testing for Biomarkers May Offer No Easy Answers (Neurology Today®) | March 16, 2023
- ICER Releases Revised Lecanemab Evidence Report Ahead of Public Meeting (Neurology Today®) | March 1, 2023
- AAN Message on FDA Approval of Lecanemab | January 6, 2023
- Will Lecanemab Win FDA Approval? The Stakes Are High as Phase 3 Results Show Efficacy (Neurology Today®) | January 5, 2023
- Neurologists React to Lecanemab News with Swirl of Excitement, Caution (Neurology Today®) | November 3, 2022
External Resources
FDA Label | July 6, 2023
CMS Fact Sheet on CED Data Submission Portal| June 22, 2023
FDA Statement on Lecanemab Approval | January 6, 2023
Questions?
Have questions or need additional resources?